TrialHaematologica2017

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.

Pieternella Lugtenburg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.